| 冷玲,刘英勋,杨文华,等.沙美特罗替卡松联合通肺化痰汤治疗慢阻肺对肺功能及炎性因子的评估[J].中国海洋药物,2026,(3):-. |
| 沙美特罗替卡松联合通肺化痰汤治疗慢阻肺对肺功能及炎性因子的评估 |
| The evaluation of Salmeterol and Ficasone combined with Tongfei Huatan Decoction in the Treatment of Chronic Obstructive Pulmonary Disease (COPD) on Pulmonary Function and Inflammatory Factors |
| 投稿时间：2025-04-24 修订日期：2025-05-22 |
| DOI： |
| 中文关键词: 慢性阻塞性肺疾病 通肺化痰汤 炎症因子 沙美特罗替卡松 肺功能 |
| English Keywords:Chronic obstructive pulmonary disease Tongfei Huatan Decoction inflammatory factor Salmeterol and Ficasone Pulmonary function |
| Fund Project: |
|
| 摘要点击次数: 22 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 探究沙美特罗替卡松与通肺化痰汤联合应用对于重度慢性阻塞性肺疾病(COPD)患者肺功能及炎症因子水平的影响。 方法 选取2021年7月-2024年12月本院收治的80例COPD患者作为研究对象,采用随机数字表法分为联合治疗组与单独治疗组,每组各40例,观察治疗前后两组的临床疗效、肺功能、炎性因子水平、不良反应等。 结果 治疗后,联合治疗组的总有效率为90.0%,高于单独治疗组的72.5%,差异有统计学意义(P＜0.05)；治疗前,两组患者的肺功能指标：第一秒用力呼吸容积(FEV1)、用力肺活量(FVC)及FEV1/FVC无统计学差异(P＞0.05),治疗后联合治疗组患者的FEV1、FVC、FEV1/FVC明显低于单独治疗组,差异有统计学差异(P＜0.05)；治疗前后两组的呼吸困难(MRC)分级无明显差异,可能为治疗后的观察时间较短,暂未发现明显统计学差异；治疗前,联合治疗组与单独治疗组的炎性因子：肿瘤坏死因子-α(TNF-α)、血清白细胞介素-8(IL-8)、降钙素原(PCT)、高敏C反应蛋白(hs-CRP)、白细胞介素-1β(IL-1β)及人组蛋白脱乙酰基酶2(HDAC2)水平无明显差异(P＞0.05),治疗后联合治疗组炎性因子显著优于单独治疗组,差异有统计学差异(P＜0.05)；治疗前后两组患者不良反应发生差异无统计学意义(P＜0.05)。结论 沙美特罗替卡松与通肺化痰汤联合应用可对COPD患者产生积极影响,具体表现为患者肺功能、炎症因子水平的明显改善及无明显毒副作用。因此,未来有望将其应用于COPD的治疗,提供更为安全有效的治疗方案。 |
| English Summary: |
| Objective To investigate the effects of salmeterol and ficasone combined with Tongfei Huatan Decoction on lung function and inflammatory factor levels in patients with severe chronic obstructive pulmonary disease (COPD). Methods 80 cases of COPD patients in the hospital from 7 month of 2021 to 12 month of 2024 were selected as the research objects. A randomized numerical table method was used to divided them into a combined treatment group and a separate treatment group, with 40 cases in each group, and the clinical efficacy, lung function, inflammatory factor, and adverse reactions before and after treatment were observed. Results The total effective rate of the combined treatment group after treatment was 90.00%, which was higher than the 72.50% of the separate treatment group, and the difference was statistically significant (P<0.05). There was no statistically significant difference in the forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC before treatment (P?0.05). After treatment, FEV1, FVC, and FEV1/FVC of the combined treatment group were significantly lower than those of the separate treatment group, and the differences were statistically different (P<0.05). There was no significant difference in dyspnea (MRC) classification between the combined treatment group and the separate treatment group before and after treatment. It may be due to the shorter observation time after treatment that no statistical difference was found for the time being (P?0.05). There were no significant differences in inflammatory factors: tumor necrosis factor-α (TNF-α), interleukin-8 (IL-8), procalcitonin (PCT), high-sensitivity C-reactive protein (hs-CRP), interleukin-1β (IL-1β), and human histone deacetylase 2 (HDAC2) between the combination therapy group and the treatment alone group before treatment (P?0.05). Inflammatory factors were significantly better in the combined treatment group than in the separate treatment group after treatment, with a statistically significant difference (P<0.05). The difference in the occurrence of adverse reactions between the two groups of patients before and after treatment was not statistically significant (P<0.05). Conclusion Through clinical studies, it was found that combining salmeterol and ficasone with Tongfei Huatan Decoction was able to positively affect patients suffering from severe COPD, as evidenced by a significant improvement in lung function and inflammatory factor levels as well as the absence of significant toxic side effects. Therefore, it is expected to be applied to the treatment of COPD in the future to provide a safer and more effective treatment option. |
| 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|